Know Cancer

forgot password

A Phase I/II Safety, Tolerability Study of LBH589 in Combination With Sorafenib in Patients With Advanced Renal Cell Carcinoma, Soft Tissue Sarcoma and Non-small Cell Lung Carcinoma (NSCLC) of Non-squamous Histologies

Phase 1
18 Years
Open (Enrolling)
Renal Cancer, Non Small Cell Lung Cancer (NSCLC)

Thank you

Trial Information

A Phase I/II Safety, Tolerability Study of LBH589 in Combination With Sorafenib in Patients With Advanced Renal Cell Carcinoma, Soft Tissue Sarcoma and Non-small Cell Lung Carcinoma (NSCLC) of Non-squamous Histologies

Inclusion Criteria:

1. Male or female patients aged ≥ 18 years old

2. ECOG Performance Status of ≤ 2

3. Ability to provide written informed consent obtained prior to participation in the
study and any related procedures being performed

4. Part A (dose escalation): Histologically or cytologically documented metastatic renal
cell carcinoma (RCC) of all histologic types, soft tissue sarcoma (STS) limited to
the following histologies: angiosarcoma, liposarcoma, and leiomyosarcoma, or
non-squamous non-small-cell lung carcinoma (NSCLC). Parts B (RCC) and C (NSCLC) and D
(STS)(expanded cohorts). Patients with RCC must have progressive metastatic disease
and received at least one multi-kinase inhibitor (e.g., sorafenib/Nexavar or
sunitinib/Sutent), or an mTOR inhibitor (e.g., Temsirolimus). Patients with STS must
have progressive disease and have received at least two therapeutic regimens
(first-line, second-line treatments).

For patients with metastatic NSCLC, they must have received two standard therapeutic
regimens (first-line and second-line treatments).

In Part A, evaluable disease by radiology and/or a recognized serum tumor marker is
required. In Parts B, C, and D measurable disease by RECIST is required

5. Predicted life expectancy ≥ 12 weeks

6. Patients may have had prior therapy, providing the following conditions are met:

Patients must have recovered from any treatment related toxicities (with the
exception of alopecia) to ≤ CTC grade 1 (fatigue, and neurotoxicity at grade 2 are
permissible if stable for >3 months) prior to registration.

1. Chemotherapy: A minimum of 5 predicted half-lives of the agent must have elapsed
between the end of treatment and registration on to the study. When halflives
are not available the principle of 2 weeks for once daily medications and 3
weeks for agents given less frequently will be adopted, but discussion with the
principal investigator is recommended.

2. Radiation: Patients may have had prior radiation therapy that has not exceeded
25% of bone marrow reserve provided that they have recovered from the acute,
toxic effects of radiotherapy prior to registration. A minimum of 7 days must
have elapsed between the end of radiotherapy to non-target lesions and
registration into the study (minimum of 28 days for target lesions).

3. Surgery: Previous surgery is permitted provided that wound healing has occurred
prior to registration.

7. Patients must meet the following laboratory criteria:

- Hematology:

- Neutrophil count of >1500/mm3

- Platelet count of > 100,000/mm3L

- Hemoglobin ≥ 9 g/dL

- Biochemistry:

- AST/SGOT and ALT/SGPT ≤ 2.5 x upper limit of normal (ULN) or ≤ 5.0 x ULN if the
transaminase elevation is due to disease involvement

- Serum bilirubin ≤ 1.5 x ULN

- Serum creatinine ≤ 2.0 x ULN or 24-hour creatinine clearance ≥ 50 ml/min

- Total serum calcium (corrected for serum albumin) or ionized calcium ≥ LLN

- Serum potassium ≥ LLN

- Serum sodium ≥ LLN

- Serum albumin ≥ LLN or 2.5 g/dl

- Patients with any elevated Alkaline Phosphatase due to bone metastasis can be

8. INR < 1.5 or a PT/PTT within normal limits. Patients receiving anti-coagulation
treatment with an agent such as warfarin or heparin may be allowed to participate.
For patients on warfarin, the INR should be measured prior to initiation of
sorafenib/LBH589 and monitored at least weekly, or as defined by the local standard
of care, until the INR is stable. LBH589 and sorafenib may elevate the INR in those
on coumadin derivatives

9. Patients must be clinically euthyroid (patients may be on thyroid hormone

10. Baseline MUGA or ECHO must demonstrate LVEF ≥ the lower limit of the institutional

11. Supportive therapy including bisphosphonates is permissible. Previous use of myeloid
and erythroid growth factor support is permissible, but not within 2 weeks of
commencement of study. Primary prophylactic use of myeloid and erythroid growth
factors is not permitted within the study, but intervention or secondary prophylaxis
is permitted if instituted following the documentation of ≥ grade 3 neutropenia or ≥
grade 2 anemia (hemoglobin)

12. Patient must be accessible for repeat dosing and follow-up

13. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test
within 7 days of the first administration of study treatment. and must be willing to
use two methods of contraception one of them being a barrier method during the study
and for 3 months after last study drug administration

Exclusion criteria:

1. NSCLC of squamous histology.

2. Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer

3. Patients who will need valproic acid for any medical condition during the study or
within 5 days prior to first LBH589 treatment

4. Known or suspected allergy to sorafenib or LBH589

5. Impaired cardiac function including any one of the following:

- Screening ECG with a QTc > 450 msec prior to enrollment to the study

- Patients with congenital long QT syndrome

- History of sustained ventricular tachycardia

- Any history of ventricular fibrillation or torsades de pointes

- Bradycardia defined as heart rate < 50 beats per minute. Patients with a
pacemaker and heart rate ≥ 50 beats per minute are eligible.

- Patients with a myocardial infarction or unstable angina within 6 months of
study entry

- Congestive heart failure (NY Heart Association class III or IV)

- Right bundle branch block and left anterior hemiblock (bifasicular block)

6. Uncontrolled hypertension

7. Concomitant use of drugs with a risk of causing torsades de pointes (See Appendix

8. Concomitant use of CYP3A4 inhibitors (See Appendix 1.-2)

9. Patients with unresolved diarrhea > CTCAE grade 1

10. Impairment of gastrointestinal (GI) function or GI disease that may significantly
alter the absorption of oral LBH589

11. Other concurrent severe and/or uncontrolled medical conditions

12. Patients who have undergone major surgery < 4 weeks prior to starting study drug or
who have not recovered from side effects of such therapy

13. Concomitant use of any anti-cancer therapy or radiation therapy

14. Women who are pregnant or breast feeding or women of childbearing potential
(WOCBP)not willing to use a double barrier method of contraception during the study
and 3 months after the end of treatment. One of these methods of contraception must
be a barrier method. WOCBP are defined as sexually mature women who have not
undergone a hysterectomy or who have not been naturally postmenopausal for at least
12 consecutive months (i.e., who has had menses any time in the preceding 12
consecutive months).

Women of childbearing potential (WOCBP) must have a negative serum pregnancy test
within 7 days of the first administration of oral LBH589

15. Male patients whose sexual partners are WOCBP not using a double method of
contraception during the study and 3 months after the end of treatment. One of these
methods must be a condom

16. Patients with a history of another primary malignancy within 5 years other than
curatively treated CIS of the cervix, or basal or squamous cell carcinoma of the skin

17. Patients with known positivity for human immunodeficiency virus (HIV) ) or hepatitis
C; baseline testing for HIV and hepatitis C is not required

18. Patients with any significant history of non-compliance to medical regimens or with
inability to grant a reliable informed consent

19. Symptomatic brain metastases which are not stable, require steroids, or
anti-epileptic medication.

20. Thrombolic or embolic events such as a cerebrovascular accident including transient
ischemic attacks within the past 6 months.

21. Pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of first dose of
study drug.

22. Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of
study drug.

23. Serious non-healing wound, ulcer, or bone fracture.

24. Use of St. John's Wort or rifampin (rifampicin).

25. Any condition that impairs patient's ability to swallow whole pills.

26. Active or uncontrolled infections, or serious illnesses or medical conditions that
could interfere with the patient's ongoing participation in the study.

27. Any other condition, which in the investigator's opinion, would compromise the safety
of the patient or the feasibility of completing the study objectives through the use
of this patient.

Note: Investigators must ensure that the patients enrolled in the study will be available
for all study procedures, including dosing, toxicity assessment and follow up and have the
ability to understand the requirements of the study and provide signed informed consent.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Maximum tolerated dose (MTD)defined as the highest combination of sorafenib and LBH589

Outcome Time Frame:

Point in time when no more than 1 of 6 patients has a Dose Limiting Toxicity (DLT) in cycle 1

Safety Issue:


Principal Investigator

Harry Drabkin, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Medical University of South Carolina


United States: Food and Drug Administration

Study ID:




Start Date:

November 2009

Completion Date:

November 2016

Related Keywords:

  • Renal Cancer
  • Non Small Cell Lung Cancer (NSCLC)
  • Renal Cancer
  • Non Small Cell Lung Cancer (NSCLC)
  • Solid Tumor
  • Sorafenib
  • Panobinostat
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Lung Neoplasms



Medical University of South Carolina Hollings Cancer Center Charleston, South Carolina  29425